Vaxcyte, Inc. — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2026-02-26

Reporting Person: Cowan Elvia (SVP, Finance & CAO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Common Stock	A	10681	—	Acquired	24215	Direct
2026-02-26	Common Stock	M	7716	$25.92	Acquired	31931	Direct
2026-02-28	Common Stock	F	243	$61.98	Disposed	31688	Direct
2026-03-02	Common Stock	F	326	$61.98	Disposed	31362	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Stock Option (right to buy)	$60	A	17855	Acquired	2036-02-26	Common Stock (17855)	Direct
2026-02-26	Stock Option (right to buy)	$25.92	M	7716	Disposed	2032-08-08	Common Stock (7716)	Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F2: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

F3: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

F4: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.